GWP
ATNM icon

Gen-Wealth Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Gen-Wealth Partners’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Sell
105,111
-2,000
-2% -$2.31K 0.03% 329
2026
Q1 		$107K Sell
107,111
-20
-0% -$24 0.03% 320
2025
Q4 		$146K Sell
107,131
-2,250
-2% -$3.28K 0.05% 290
2025
Q3 		$175K Buy
+109,381
New +$178K 0.06% 257

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Gen-Wealth Partners's ATNM Position: Q2 2026 in Review

Gen-Wealth Partners reduced its Actinium Pharmaceuticals (ATNM) stake by 1.9% in Q2 2026, selling an estimated $2.31K and leaving 105,111 shares worth $103K. The position accounts for 0.03% of the portfolio, ranked #329.

Gen-Wealth Partners first reported a position in ATNM in Q3 2025 and has held it in 4 quarters since. The position peaked at $175K in Q3 2025. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Gen-Wealth Partners held 105,111 shares of Actinium Pharmaceuticals worth $103K as of Q2 2026.
  • Gen-Wealth Partners sold 2,000 Actinium Pharmaceuticals shares in Q2 2026, an estimated $2.31K.
  • Actinium Pharmaceuticals made up 0.03% of Gen-Wealth Partners's portfolio in Q2 2026, its #329 holding.
  • Gen-Wealth Partners first reported a position in Actinium Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Gen-Wealth Partners's Actinium Pharmaceuticals position peaked at $175K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.